44 results about "Systemic lupus" patented technology

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving systemic lupus erythematosus and a preparation method thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15-30 parts of dry rehmannia, 12-26 parts of calcined turtle shell, 13-25 parts of chicken tendon ginseng, 11-18 parts of red peony root, 10-20 parts of white flower snake tongue grass, 6-18 parts of small rosmarinus officinalis, 4-15 parts of artemisia annua, 5-10 parts of centella asiatica, 4-12 parts of cimicifuga foetida, 3-10 parts of coix seed, 2-9 parts of bergamot slice, and 3-7 parts of raw licorice. Test results show that the traditional Chinese medicine composition for improving systemic lupus erythematosus prepared by the application can inhibit the expression of IL-10 and IL-17 in serum, reduce anti-dsDNA antibodies in serum, significantly improve the clinical symptoms of systemic lupus erythematosus, and has a wide application prospect.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application provides a trophoblast organ-on-chip system for simulating a maternal-fetal interface of a systemic lupus erythematosus model based on an organ chip and a construction method thereof, the system taking an organ chip as a carrier and comprising three core parts of a trophoblast organ, an endometrial chip and an SLE disease model. The application completes separation culture and characterization of the trophoblast organ, multi-cell co-culture construction and characterization of the endometrial chip, and then constructs a pathological model, and the three parts cooperatively form a three-dimensional maternal-fetal interface. The system can clearly observe the dynamic process of the trophoblast organ invading the endometrial chip, can detect the continuous secretion of hCG and SLE-related inflammatory factors, and breaks through the defects of the prior art model, such as low authenticity, inability to dynamically observe, single detection dimension and lack of standardization, and has both physiological and pathological adhesion and experimental repeatability, can multi-dimensionally characterize the cell phenotype and function of the maternal-fetal interface, and provides an in-vitro research platform for the pathological mechanism research of the SLE pregnancy-related abnormal maternal-fetal interface.

The application relates to application of a reagent for detecting expression levels of a PSIP1 gene or a coded protein LEDGF / p75 in preparation of a product for evaluating systemic lupus erythematosus disease activity, which makes up for the problems of insufficient sensitivity and specificity of existing evaluation indexes; the application also discloses a key role of the PSIP1 gene in a pathogenesis mechanism of systemic lupus erythematosus, and clearly shows the relationship between the PSIP1 gene in T cells and cell cycle arrest, cell aging and abnormal immune function, so as to provide a theoretical basis for target regulation of the PSIP1 to improve T cell function and delay or block disease progression; the application firstly proposes that the expression levels of the PSIP1 / LEDGF / p75 are detected to be used for evaluating systemic lupus erythematosus disease activity, auxiliary diagnosis, prognosis prediction and treatment effect monitoring, so as to provide a brand-new tool and direction for precise diagnosis, activity evaluation, prognosis judgment and future target treatment development of systemic lupus erythematosus.

The application discloses a traditional Chinese medicine composition for treating systemic lupus erythematosus (SLE) related pulmonary arterial hypertension and application, and relates to the technical field of traditional Chinese medicine, wherein the composition is prepared from pueraria, gotukola, salvia miltiorrhiza, chuanxiong, radix scrophulariae, poria cocos, wheat bran-fried atractylodes, dried tangerine or orange peel, prepared pinellia, baked licorice, immature bitter orange fruit and gotukola, and has the functions of activating blood circulation to remove blood stasis and clearing heat and resolving toxins, and is aimed at the pathogenesis of the heat-toxin blood stasis syndrome of SLE-PAH. The application further provides a preparation method of the composition. The composition can effectively reduce the pulmonary arterial pressure of a model animal, relieve right ventricular hypertrophy and pulmonary vascular remodeling, and improve the oxidation stress level in experiments. In combination with western medicine, the composition can significantly improve the exercise endurance of a patient, improve the pulmonary arterial systolic pressure and key serological indexes, and has a better curative effect than simple western medicine and good safety, thereby providing a safe and effective traditional Chinese medicine composition for treating SLE-PAH.

Various embodiments of the present application provide binding molecules for B-lymphocyte antigens (e.g., CD19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD19 and CD20). Embodiments of the present application also provide cells expressing such binding molecules, therapeutic compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigens (e.g., CD19 and CD20), including hematological cancers, autoimmune diseases (e.g., multiple sclerosis and systemic lupus erythematosus).

Methods for characterizing disease activity in a systemic lupus erythematosus (SLE) patient. Methods include obtaining a blood, serum, plasma, or urine sample from the patient; assessing the sample for expression of a biomarker selected from the group consisting of IFN-α, IL-10, BLyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4; assessing the sample for expression of an inflammatory mediator selected from the group consisting of TNFRII, Resistin, and Osteopontin (OPN); assessing the sample for an SLE-associated autoantibody specificity biomarker selected from the group consisting of dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP; and calculating a Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score may distinguish between active and low lupus disease activity. Methods of treatment are also provided including administering a treatment prior to reaching clinical disease classification after determining that the patient has the prognosis for transitioning to classified SLE.

The present invention relates to a method for identifying a compound that modulates the C-terminal Src kinase (Csk) by modulating at least one of the following features: the expression, amount, stability, biological activity of the Csk protein, and / or the interaction of the Csk protein with the lymphocyte-specific tyrosine kinase (Lck) protein in a mammalian cell. The identified compound is particularly suitable for use in the prevention or treatment of an autoimmune disease, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS), and type 1 diabetes (T1D), or an infection, such as a bacterial or viral infection, cancer, cardiovascular diseases, age-related diseases, and preferably for use in increasing cellular immunity against cancer cells.Further aspects of the invention relate to a screening method for screening for a compound and / or a pharmaceutical composition comprising the compound.

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention, and diagnosis of diseases, disorders, or inflammation, including, for example, autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis, including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of the final antibody structure are designed de novo by a computer system and its data training set, without reference to a particular reference molecule.

The present invention provides methods of treating and improving the symptoms of system lupus erythematous using obexelimab.

New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.

The application discloses a nucleic acid aptamer of LL37 antibacterial peptide and a preparation method and application thereof. The nucleic acid aptamer screened by the application has good affinity with antibacterial peptide LL37, can be used for detecting LL37, and provides a new candidate tool for diagnosing psoriasis, systemic lupus erythematosus and other autoimmune diseases based on an LL37 target.

The application discloses application of keratin 14 or a glycosylation modifier thereof in preparation of a product for treating systemic lupus erythematosus. The keratin 14, as a component of skin keratinocytes, has small toxic and side effects. The first research of the application shows that the keratin 14 has certain potential in treating systemic lupus erythematosus, and use of the keratin 14, a body self component, can greatly shorten research and development cost and research and development risk. The application first explores the effect of the keratin 14 in treating systemic lupus erythematosus, and provides an experimental basis for treatment of systemic lupus erythematosus.

To provide treatment methods for cutaneous lupus erythematosus and systemic lupus erythematosus. [Solution] The present invention provides a dosage regimen for an anti-blood dendritic cell antigen 2 antibody for use in the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. The present invention relates, in part, to a dosage regimen for an anti-BDCA2 antibody for use in the treatment of CLE and SLE. In a first aspect, the present invention features a method for treating CLE or SLE in a human subject requiring treatment. The method comprises subcutaneously administering an anti-BDCA2 antibody to the human subject at a dose of 225 mg every four weeks.

This invention relates to the field of biomedical technology, and more particularly to a CD38-targeting CAR-CD8+ iTreg cell, its preparation method, and its application. This invention utilizes CD8+ iTreg cells combined with the construction technology of a CD38-targeting chimeric antigen receptor (CAR) to generate novel CD38-targeting CAR-CD8+ iTreg cells. For the first time, these novel CD38-targeting CAR-CD8+ iTreg cells were applied to the treatment of systemic lupus erythematosus (SLE), demonstrating that they can effectively alleviate SLE and lupus nephritis, exhibiting good therapeutic effects. The mechanism may be that the CD38-targeting CAR-CD8+ iTreg cells exert a protective effect on lupus mice by depleting activated T cells, B cells, and NK cells that highly express CD38.

The objectives are to provide an anti-PAD4 antibody with superior properties, or to provide an excellent method for preventing or treating rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, or graft-versus-host disease, etc. [Solution] The present invention provides an anti-PAD4 antibody or an antibody fragment thereof, wherein HCDR1 contains the amino acid sequence of SEQ ID NO: 1, HCDR2 contains the amino acid sequence of SEQ ID NO: 2, HCDR3 contains the amino acid sequence of SEQ ID NO: 3, LCDR1 contains the amino acid sequence of SEQ ID NO: 4, LCDR2 contains the amino acid sequence of SEQ ID NO: 5, and LCDR3 contains the amino acid sequence of SEQ ID NO: 6.

The application discloses an application of a NAT10 overexpression agent in preparation of a drug for treating systemic lupus erythematosus, wherein the NAT10 overexpression agent is a lentivirus for overexpression of NAT10, the accession number of the CDS sequence of the NAT10 gene in the NCBI database is NM_024662.3, and the drug for treating systemic lupus erythematosus refers to a drug capable of reducing neutrophil iron death and reducing the disease activity of systemic lupus erythematosus; the NAT10 overexpression agent provided by the application can overexpress the NAT10 gene through cell experiments, has a significant effect on reducing the neutrophil iron death level of a systemic lupus erythematosus patient and reducing the disease activity of systemic lupus erythematosus, and has a gene therapy purpose on systemic lupus erythematosus, thereby providing a new targeted therapy drug for clinical treatment of systemic lupus erythematosus.

The application discloses application of targeting ENPP1 in treatment of systemic lupus erythematosus, and the systemic lupus erythematosus has CD4 + T cell abnormal differentiation and induction of CD4 + T cell abnormal differentiation mtDNA, new recognizable molecule ENPP1 exists in mtDNA, and CD4 + T cell differentiation is induced by ENPP1 as a target point for treating systemic lupus erythematosus. The application provides the application of targeting ENPP1 in treatment of systemic lupus erythematosus, and the application explores the action mechanism of mtDNA on CD4 + T cell differentiation, focuses on a new recognizable molecule ENPP1 of mtDNA, and CD4 + T cell differentiation is induced by ENPP1 as a target point for treating systemic lupus erythematosus, and a new strategy for treating systemic lupus erythematosus is excavated.

Use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and / or preventing an inflammatory or immune disease are provided. Compounds of A1-A52, B1-B5, or C1-C36 are used in the preparation of a drug for treating and / or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.

The present disclosure provides methods of treating a systemic lupus erythematosus (e.g. highly active, severe, treatment-refractory systemic lupus erythematosus) by administering a chimeric antigen receptor T cell (CAR-T cell) comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor. The present disclosure also provides a dose infusion bag comprising a composition comprising CAR-T cells comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor.

The present invention relates to a biomarker composition for predicting onset of systemic lupus erythematosus, comprising, as an effective ingredient, a protein expressed in CD8+ T cells or a gene encoding the same.

The application provides biomarkers for diagnosing systemic lupus erythematosus and application thereof, and belongs to the field of biological medicine. The biomarkers are at least one of the following five proteins N-glycopeptides, specifically: IgG1_N299-HexNAc(3)Hex(4); F2_N121-HexNAc(2)Hex(12); C3_N85-HexNAc(2)Hex(1); VTN_N169-HexNAc(2)Hex(4); APOB_N1523-HexNAc(3)Hex(4)NeuAc(1). The application proposes the five protein N-glycopeptides as biomarkers for diagnosing SLE, and has the advantages of high accuracy, high sensitivity and high specificity, and provides a new target for the diagnosis and intervention improvement of SLE patients.

The application provides a systemic lupus erythematosus activity detection marker composition and a model construction and application thereof, and belongs to the technical field of disease medical detection.The systemic lupus erythematosus activity detection marker composition provided by the application comprises the combination of V genes and J genes of TCR alpha chains and TCR beta chains of CD4+ T cells and CD8+ T cells, the combination of V genes and J genes of B cell BCR IgH chains, and CD38, S100A11, IFITM3, GPX1 and NCF1 genes.The application provides a method for assisting in diagnosing the activity period of systemic lupus erythematosus based on immunome sequencing and transcriptome sequencing, can distinguish the immunome population of healthy people, SLE stable period and SLE activity period through multi-parameter analysis, and can distinguish the population with severe symptoms in the SLE activity population, and provides a new strategy for the accurate diagnosis of SLE.

Methods for characterizing disease activity in patients with systemic lupus erythematosus (SLE). These methods include obtaining blood, serum, plasma, or urine samples from the patient; assessing the expression of biomarkers selected from IFN-α, IL-10, BlyS, IL-7, IFN-γ, TRAIL, IL-15, IP-10 / CXCL10, and IL-4 in the samples; assessing the expression of inflammatory mediators selected from TNFRII, resistin, and osteopontin (OPN) in the samples; assessing SLE-related autoantibody-specific biomarkers selected from dsDNA, chromatin, RiboP, Ro / SSA, La / SSB, Sm, SmRNP, and RNP in the samples; and calculating the Lupus Disease Activity (Immune) Index (LDAII / L-DAI) score. The LDAII / L-DAI score can distinguish between active and low lupus disease activity. Treatment methods are also provided, including administration after determining that the patient has a prognostic risk of transitioning to classified SLE but before reaching the clinical disease classification.